PMID- 36130866
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230320
IS  - 1995-9133 (Electronic)
IS  - 1684-1182 (Linking)
VI  - 56
IP  - 2
DP  - 2023 Apr
TI  - Characterization of oxacillin-resistant Staphylococcus lugdunensis isolated from 
      sterile body fluids in a medical center in Taiwan: A 12-year longitudinal 
      epidemiological study.
PG  - 292-298
LID - S1684-1182(22)00150-5 [pii]
LID - 10.1016/j.jmii.2022.08.021 [doi]
AB  - BACKGROUND: In this study, our objective was to characterize Staphylococcus 
      lugdunensis isolated from sterile body fluids (SBFs) in a medical center in 
      Taiwan between 2009 and 2020. METHODS: We used MALDI-TOF MS, disk diffusion 
      testing, agar dilution assay, SCCmec typing, and antibiotic resistance gene 
      screening to identify and investigate the characteristics of oxacillin-resistant 
      S. lugdunensis (ORSL). RESULTS: A total of 438 S. lugdunensis isolates were 
      collected and 146 (33.3%) isolates were identified as ORSL. SCCmec type V was 
      dominant (65.7%) in our ORSL isolates, followed by SCCmec type II (18.5%), and 
      type IV (8.9%). After 2013, a slight increase in SCCmec types IV and V was 
      revealed. Moreover, all ORSL isolates with type II and untypable SCCmec were 
      highly resistant to oxacillin (MIC >32 mug/mL), compared to ORSL that had SCCmec 
      types IV, V, and VT. All 146 ORSL isolates were resistant to penicillin and 
      susceptible to teicoplanin and vancomycin. High resistance rates of ORSL to 
      clindamycin (43.2%), erythromycin (43.2%), gentamicin (78.1%) and tetracycline 
      (46.6%) was observed. Moreover, only two (1.4%) and six (4.1%) ORSL isolates were 
      resistant to trimethoprim/sulfamethoxazole and ciprofloxacin, respectively. The 
      erythromycin-resistant ORSL isolates mostly exhibited constitutive MLS(B) 
      resistant phenotype (61/63, 96.8%) and contained either ermC alone (27/63, 42.9%) 
      or a combination of ermC with ermA (28/63, 44.4%). CONCLUSION: Our present study 
      showed a stable rate of ORSL from SBFs during 2009-2020. Moreover, teicoplanin, 
      vancomycin, trimethoprim/sulfamethoxazole, and ciprofloxacin were shown to be 
      highly efficient for the treatment of ORSL in vitro.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Chang, Shih-Cheng
AU  - Chang SC
AD  - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, 
      Taiwan; Department of Medical Biotechnology and Laboratory Science, Chang Gung 
      University, Taoyuan, Taiwan.
FAU - Hidrosollo, Jazon Harl
AU  - Hidrosollo JH
AD  - Institute of Microbiology and Immunology, College of Life Sciences, National Yang 
      Ming Chiao Tung University, Taipei, Taiwan.
FAU - Lin, Lee-Chung
AU  - Lin LC
AD  - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, 
      Taiwan.
FAU - Ou, Yu-Hsiang
AU  - Ou YH
AD  - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, 
      Taiwan.
FAU - Kao, Cheng-Yen
AU  - Kao CY
AD  - Institute of Microbiology and Immunology, College of Life Sciences, National Yang 
      Ming Chiao Tung University, Taipei, Taiwan. Electronic address: 
      kaocy@nycu.edu.tw.
FAU - Lu, Jang-Jih
AU  - Lu JJ
AD  - Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, 
      Taiwan; Department of Medical Biotechnology and Laboratory Science, Chang Gung 
      University, Taoyuan, Taiwan; Department of Medicine, College of Medicine, Chang 
      Gung University, Taoyuan, Taiwan. Electronic address: janglu45@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220909
PL  - England
TA  - J Microbiol Immunol Infect
JT  - Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
JID - 100956211
RN  - UH95VD7V76 (Oxacillin)
RN  - 6Q205EH1VU (Vancomycin)
RN  - 61036-62-2 (Teicoplanin)
RN  - 0 (Anti-Bacterial Agents)
RN  - 5E8K9I0O4U (Ciprofloxacin)
RN  - 63937KV33D (Erythromycin)
RN  - JE42381TNV (Sulfamethoxazole)
RN  - AN164J8Y0X (Trimethoprim)
SB  - IM
MH  - Humans
MH  - Oxacillin/pharmacology
MH  - *Staphylococcus lugdunensis/genetics
MH  - *Methicillin-Resistant Staphylococcus aureus/genetics
MH  - Vancomycin
MH  - *Staphylococcal Infections/epidemiology
MH  - Teicoplanin
MH  - Taiwan/epidemiology
MH  - Microbial Sensitivity Tests
MH  - Anti-Bacterial Agents/pharmacology
MH  - *Body Fluids
MH  - Ciprofloxacin
MH  - Erythromycin
MH  - Sulfamethoxazole
MH  - Trimethoprim
OTO - NOTNLM
OT  - Antibiotic susceptibility
OT  - Oxacillin resistance
OT  - SCCmec
OT  - Staphylococcus lugdunensis
OT  - Sterile body fluids
COIS- Declaration of competing interest All authors have no conflicts of interest to 
      declare.
EDAT- 2022/09/22 06:00
MHDA- 2023/03/21 06:00
CRDT- 2022/09/21 22:04
PHST- 2022/06/13 00:00 [received]
PHST- 2022/08/21 00:00 [revised]
PHST- 2022/08/28 00:00 [accepted]
PHST- 2022/09/22 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2022/09/21 22:04 [entrez]
AID - S1684-1182(22)00150-5 [pii]
AID - 10.1016/j.jmii.2022.08.021 [doi]
PST - ppublish
SO  - J Microbiol Immunol Infect. 2023 Apr;56(2):292-298. doi: 
      10.1016/j.jmii.2022.08.021. Epub 2022 Sep 9.